These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34221866)

  • 1. Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.
    Wang Z; Zhang Z; Li Y; Sun L; Peng D; Du D; Zhang X; Han L; Zhao L; Lu L; Du H; Yuan S; Zhan M
    Acta Pharm Sin B; 2021 Jun; 11(6):1526-1540. PubMed ID: 34221866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
    Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
    Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
    Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
    Stein EM
    Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
    Abou Dalle I; DiNardo CD
    Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
    DiNardo CD; Venugopal S; Lachowiez C; Takahashi K; Loghavi S; Montalban-Bravo G; Wang X; Carraway H; Sekeres M; Sukkur A; Hammond D; Chien K; Maiti A; Masarova L; Sasaki K; Alvarado Y; Kadia T; Short NJ; Daver N; Borthakur G; Ravandi F; Kantarjian HM; Patel B; Dezern A; Roboz G; Garcia-Manero G
    Blood Adv; 2023 Jun; 7(11):2378-2387. PubMed ID: 35973199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.
    Yao K; Liu H; Liu P; Liu W; Yang J; Wei Q; Cao P; Lai Y
    Comput Biol Chem; 2020 Jun; 86():107261. PubMed ID: 32361585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (2
    Idle JR; Seipel K; Bacher U; Pabst T; Beyoğlu D
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33019704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.
    Reed DR; Elsarrag RZ; Morris AL; Keng MK
    Cancer Manag Res; 2019; 11():8073-8080. PubMed ID: 31564968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.
    Murali P; Karuppasamy R
    J Mol Model; 2022 Dec; 29(1):6. PubMed ID: 36484830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.
    Khalil AF; El-Moselhy TF; El-Bastawissy EA; Abdelhady R; Younis NS; El-Hamamsy MH
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157411. PubMed ID: 36629449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
    Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
    J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
    Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
    Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
    Thomas D; Majeti R
    Cancer Discov; 2017 May; 7(5):459-461. PubMed ID: 28461409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.